menu
    • menu
    [{"orgOrder":0,"company":"Zentiva","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"12","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Biocon","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Adalvo","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Tillomed Laboratories Ltd","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Mabxience","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"5-Fluorouracil","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"12","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Urology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Finasteride","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Prague Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sertraline Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Prague Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Prague Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Zentiva","sponsor":"Biocon","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"12","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Raltegravir Potassium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"14","companyTruncated":"Zentiva \/ Zentiva"}]

    Find Clinical Drug Pipeline Developments & Deals by Prague Scientific

    Menu

    Prague Scientific

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Raltegravir Potassium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Lupin Ltd

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Generic HIV raltegravir medicines approved

                            Details : Raltegravir is an approved, small molecule, HIV-1 integrase inhibitor, available as a film coated tablet for the treatment of HIV in adult and paediatric patients weighing at least 40kg.

                            Brand Name : Raltegravir-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 22, 2024

                            Lead Product(s) : Raltegravir Potassium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Lupin Ltd

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Biocon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biocon to Obtain Approval for Diabetes Drug, Liraglutide in UK

                            Details : Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.

                            Brand Name : Liraglutide-Generic

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 28, 2024

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Biocon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            A Convenient Treatment Option for Thromboembolic Events

                            Details : Rivaroxaban oral suspension, inhibits free FXa and prothrombinase activity. It has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, it decreases thrombin generation.

                            Brand Name : Rivaroxaban-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 10, 2023

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Undisclosed

                            Recipient : Adalvo

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology

                            Details : Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Adalvo

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Tillomed Laboratories Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Zentiva Completes Major Product Acquisition from Tillomed Spain

                            Details : Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 16, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Tillomed Laboratories Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zent2U Announces Successful Pivotal Bioequivalence Study Results on Omeprazole Immediate Release Capsules

                            Details : Omeprazole magnesium is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid...

                            Brand Name : Omeprazole Magnesium-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 25, 2022

                            Lead Product(s) : Omeprazole Magnesium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Zentiva

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Recipient : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Biocon Limited Enters Into a Commercialization Agreement With Zentiva in Europe

                            Details : Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe.

                            Brand Name : Liraglutide-Generic

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            November 23, 2022

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Recipient : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Finasteride,Tadalafil

                            Therapeutic Area : Urology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zent2U Will Be the First Offering EU Dossier for Finasteride / Tadalafil 5 Mg / 5 Mg Fixed-Dose Combination

                            Details : Finasteride and tadalafil combination is used to treat men with benign prostatic hyperplasia (BPH). Tadalafil is a PDE5 inhibitor and finasteride blocks the action of 5-alpha-reductase which will increase testosterone levels in the body, which decreases ...

                            Brand Name : Finasteride/Tadalafil-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 26, 2021

                            Lead Product(s) : Finasteride,Tadalafil

                            Therapeutic Area : Urology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sitagliptin Phosphate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zent2U Announces Successful Pivotal BE Trial on Sitagliptin Development

                            Details : Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.

                            Brand Name : Sitagliptin-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2021

                            Lead Product(s) : Sitagliptin Phosphate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Prague Scientific

                            Czech Republic arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sertraline Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zent2U announces Completion of Bioequivalence Trials on Sertraline

                            Details : Sertraline hydrochloride potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT). It is indicated for the treatment of MDD, PTSD, PMDD, panic disorder, and social anxiety disorder.

                            Brand Name : Sertraline Hydrochloride-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 12, 2021

                            Lead Product(s) : Sertraline Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth